Breast cancer prevention by antihormones and other drugs. Where do we stand?

Matteo Lazzeroni, Andrea DeCensi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Breast cancer is the most common cancer in women worldwide. The selective estrogen-receptor (ER) modulators tamoxifen and raloxifene are approved by the Food and Drug Administration for the preventive therapy of breast cancer. Other drugs have shown promise but need further assessment. In the present review, we present an update of the chemoprevention of ER-positive breast cancer and discuss the potential role of metformin and aspirin, 2 drugs other than the specific "antihormones.".

Original languageEnglish
Pages (from-to)657-672
Number of pages16
JournalHematology/Oncology Clinics of North America
Volume27
Issue number4
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Breast Neoplasms
Pharmaceutical Preparations
Selective Estrogen Receptor Modulators
Needs Assessment
Metformin
Chemoprevention
United States Food and Drug Administration
Tamoxifen
Estrogen Receptors
Aspirin
Neoplasms
Therapeutics
Raloxifene Hydrochloride

Keywords

  • Aromatase Inhibitors
  • Aspirin
  • Breast cancer chemoprevention
  • Metformin
  • Selective estrogen receptor modulators

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Breast cancer prevention by antihormones and other drugs. Where do we stand? / Lazzeroni, Matteo; DeCensi, Andrea.

In: Hematology/Oncology Clinics of North America, Vol. 27, No. 4, 08.2013, p. 657-672.

Research output: Contribution to journalArticle

@article{03e45410ec934dec88758429a878698e,
title = "Breast cancer prevention by antihormones and other drugs. Where do we stand?",
abstract = "Breast cancer is the most common cancer in women worldwide. The selective estrogen-receptor (ER) modulators tamoxifen and raloxifene are approved by the Food and Drug Administration for the preventive therapy of breast cancer. Other drugs have shown promise but need further assessment. In the present review, we present an update of the chemoprevention of ER-positive breast cancer and discuss the potential role of metformin and aspirin, 2 drugs other than the specific {"}antihormones.{"}.",
keywords = "Aromatase Inhibitors, Aspirin, Breast cancer chemoprevention, Metformin, Selective estrogen receptor modulators",
author = "Matteo Lazzeroni and Andrea DeCensi",
year = "2013",
month = "8",
doi = "10.1016/j.hoc.2013.05.009",
language = "English",
volume = "27",
pages = "657--672",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Breast cancer prevention by antihormones and other drugs. Where do we stand?

AU - Lazzeroni, Matteo

AU - DeCensi, Andrea

PY - 2013/8

Y1 - 2013/8

N2 - Breast cancer is the most common cancer in women worldwide. The selective estrogen-receptor (ER) modulators tamoxifen and raloxifene are approved by the Food and Drug Administration for the preventive therapy of breast cancer. Other drugs have shown promise but need further assessment. In the present review, we present an update of the chemoprevention of ER-positive breast cancer and discuss the potential role of metformin and aspirin, 2 drugs other than the specific "antihormones.".

AB - Breast cancer is the most common cancer in women worldwide. The selective estrogen-receptor (ER) modulators tamoxifen and raloxifene are approved by the Food and Drug Administration for the preventive therapy of breast cancer. Other drugs have shown promise but need further assessment. In the present review, we present an update of the chemoprevention of ER-positive breast cancer and discuss the potential role of metformin and aspirin, 2 drugs other than the specific "antihormones.".

KW - Aromatase Inhibitors

KW - Aspirin

KW - Breast cancer chemoprevention

KW - Metformin

KW - Selective estrogen receptor modulators

UR - http://www.scopus.com/inward/record.url?scp=84881274975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881274975&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2013.05.009

DO - 10.1016/j.hoc.2013.05.009

M3 - Article

VL - 27

SP - 657

EP - 672

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 4

ER -